This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

PDI, Inc. Reinvents Sales Rep And Physician Interaction With New Digital Communications Network

Stocks in this article: PDII

PARSIPPANY, N.J., Jan. 14, 2014 /PRNewswire/ --  PDI, Inc. (Nasdaq: PDII), today announced the launch of PD One , a proprietary technology platform aimed at expanding relationships between pharmaceutical and life science manufacturers and health care providers. The subscription-based platform enables clients to extend personal and brand interactions with physicians through a secure, professional networking platform that features direct messaging and dynamic content. PDI also announced that it has contracted with a leading pharmaceutical company to provide PD One to select sales representatives across the U.S., while its own Interpace Diagnostics subsidiary will also launch the platform with its sales force.

(Logo: http://photos.prnewswire.com/prnh/20140114/NY45872LOGO )

"With PD One, pharmaceutical marketers have a new tool that bridges the gap between the direct sales model and digital marketing, creating an entirely new communication channel to more effectively engage with health care practitioners," said Nancy Lurker. "PD One provides pharmaceutical manufacturers with a communications platform that allows their sales force to offer unique, value-added services to better reach and engage physicians online."

PD One provides authorized sales representatives the ability to share compliant, secure content and to interact directly with health care providers. Through the PD One platform, pharmaceutical and life science companies can deliver content, send and receive emails, conduct e-detailing, create and manage content on customized microsites, and respond to information and sample requests through a single interface.

The new platform complements PDI's award-winning companion site, Medical Bag , a content-rich, multi-functional digital environment that receives more than 50,000 visits by medical professionals each month. With more than 400,000 verified physicians in its database, Medical Bag offers continuing medical education (CME) from myCME.com and drug information from MPR. Both myCME and MPR are properties of partner, Haymarket Media, Inc. Medical Bag also includes RSS newsfeeds from leading medical journals and sponsored banner advertisements, along with unique content and specialty therapeutic area pages.

"We developed PD One to transform how life science companies communicate with clinicians," said Ron Scalici, Chief Innovation Officer, Group DCA. "By leveraging the success of The Medical Bag, manufacturers can deliver targeted information and intellectually stimulating content to clinicians – when they want to receive it - within a highly networked, multifunctional digital environment."

"PD One unites PDI's strengths across the commercialization, sales and digital marketing spectrum," said Frank Saia, General Manager, Group DCA. "With physicians increasingly turning to technology for information, PD One leverages the shift to mobile solutions to further empower both clinicians and manufacturers."

About PDI

PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs